Effect of SMARCA4 degradation on ID8 ovarian cancer cells senescent and not senescent.
We report the analysis of RNA sequencing aimed at understanding the effects induced by AU-15330 (SMARCA4 PROTAC)-mediated degradation of SMARCA4 in P53-deficient senescent ID8 ovarian tumour cells. Specifically, we focus on exploring the repercussions of inhibiting SMARCA4, a constituent of the SWI/SNF complex subunit, on the SASP and immune activity within cisplatin-treated senescent cancer cells. The findings will help characterise the role of SMARCA4 inhibition on senescence surveillance by Natural Killer cells. Overall design: ID8 cells were treated with either  cisplatin alone, SMARCA4 PROTAC alone, or in combination for up 6 days.